NeuroBehavioral Medicine Group | Bloomfield Hills, MI

Research site

(Unclaimed)

Location

West 4111 Andover Road Suite 100, Bloomfield Hills, Michigan, United States of America

Site insights

Top conditions

Top treatments

Aripiprazole

Eszopiclone

SHP465

Ecopipam

Cariprazine

Ubrogepant

ML-004

Dasotraline

CTx-1301

Seltorexant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 21 total trials

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults (D1AMOND)

This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults...

Enrolling

Tourette Disorder

Drug: Ecopipam Hydrochloride

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and ad...

Enrolling

Autism Spectrum Disorder

Drug: ML-004 Placebo

Drug: ML-004 (IR)/(ER) tablet

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population...

Active, not recruiting

Attention Deficit Hyperactivity Disorder Combined

Attention Deficit Hyperactivity Disorder

Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)

Drug: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant